Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment

The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting the search for immune modulating agents that can improve the therapeutic efficacy. The non...

Descripción completa

Detalles Bibliográficos
Autores principales: Fjæstad, Klaire Yixin, Rømer, Anne Mette Askehøj, Goitea, Victor, Johansen, Astrid Zedlitz, Thorseth, Marie-Louise, Carretta, Marco, Engelholm, Lars Henning, Grøntved, Lars, Junker, Niels, Madsen, Daniel Hargbøl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881216/
https://www.ncbi.nlm.nih.gov/pubmed/35017664
http://dx.doi.org/10.1038/s41388-021-02170-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881216/
https://www.ncbi.nlm.nih.gov/pubmed/35017664
http://dx.doi.org/10.1038/s41388-021-02170-0

Ejemplares similares